Related Experiment Video

Updated: Mar 13, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease

W Schuyler Jones1, Matthew T Roe1, Elliott M Antman2

  • 1Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.

Journal of the American College of Cardiology
|October 22, 2016
PubMed

Insights

Cardiovascular disease clinical trials are evolving due to rising costs and complexity. This review explores current US trials, registry-based studies, and the innovative ADAPTABLE pragmatic trial.

Area of Science:

  • Cardiology
  • Clinical Trials
  • Health Services Research

Background:

  • Cardiovascular disease clinical trials have significantly advanced cardiology practice over 30 years.
  • A substantial need persists for high-quality evidence due to the global rise in cardiovascular disease.
  • Traditional clinical trials face challenges including rising costs, complexity, and regulatory burdens.

Purpose of the Study:

  • To review the current landscape of cardiovascular clinical trials in the United States.
  • To highlight recently conducted registry-based clinical trials.
  • To discuss the potential attributes of the ADAPTABLE pragmatic clinical trial.

Main Methods:

  • Review of current cardiovascular clinical trials in the US.
  • Examination of recently conducted registry-based clinical trials.
  • Discussion of the ADAPTABLE pragmatic clinical trial design and potential.

Main Results:

  • Not applicable for this review-focused abstract.
  • Not applicable for this review-focused abstract.
  • Not applicable for this review-focused abstract.

Conclusions:

  • The landscape of cardiovascular clinical trials is shifting towards more efficient and patient-centered methodologies.
  • Registry-based and pragmatic trials, such as ADAPTABLE, offer potential solutions to the challenges of traditional clinical trials.
  • Continued innovation in trial design is crucial for generating high-quality evidence in cardiovascular medicine.

Keywords:
Patient-Centered Outcomes Research Instituteaspirincoronary artery diseasepragmatic clinical trial

More Related Videos

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.8K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.3K
Randomized Experiments01:13

Randomized Experiments

The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
9.2K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.5K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
793